Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Dainippon Sumitomo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Taisho HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Shionogi's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Ono's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Santen's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kyorin HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kaken's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mochida's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Shinyaku's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kissei's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Zeria's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Fuso's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of ASKA's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Wakamoto's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Torii’s Mainstay Products in FY2011
June 19, 2012
- Merck of Germany Considers Entry into Japanese Biosimilars Market
June 18, 2012
- Pharmacists Predict Further Use of Mucosta Generics: Survey
June 18, 2012
- Asklep to Establish Subsidiary in Taiwan, Buffing Up CRO Business in Asia
June 15, 2012
- Antiallergic Agent S-555739 Shows Efficacy in Combination Therapy in PIIb Study: Shionogi
June 15, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…